Potential Value of Circulatory MicroRNA122 Gene Expression As a Prognostic and Metastatic Prediction Marker for Breast Cancer

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2019 Mar 6

PMID 30835039

Citations 19

Authors

Amany A Saleh

Shimaa E Soliman

Mona Salah El-Din Habib

Suzy F Gohar

Ghada S Abo-Zeid

Affiliations

Soon will be listed here.

Abstract

Despite progress in terms of management, breast cancer still constitutes a major threat to health worldwide. Various microRNAs have been shown to play a fundamental role in tumor biology during development and progression. Therefore, our study was focused on investigating the role of circulating microRNA122 (miR-122) in breast cancer and its clinical utility as a potential easily accessible biomarker for use in the diagnostic and prognostic assessment of breast cancer. Determination of the serum CA15-3 and carcinoembryonic antigen levels was conducted using an enzyme-linked immunosorbent assay. The expression level of miR-122 was determined using real time PCR in 90 breast cancer patients and 60 healthy controls. Higher circulating miR-122 levels were found in breast cancer patients than in controls and higher miR-122 levels were observed in patients who experienced metastasis. Additionally, miR-122, at a cutoff > 2.2, had a sensitivity of 93.33% and a specificity of 90% when used to distinguish breast cancer patients from controls and was able to predict metastasis at a cutoff > 10.9 with a sensitivity of 95.83% and a specificity of 65.15%. Kaplan-Meier survival analysis revealed that high miR-122 expression is significantly associated with decreased overall survival and progression-free survival. This study concludes that circulatory miR-122 could be utilized as a diagnostic and prognostic biomarker in breast cancer patients.

Citing Articles

Associations of plasma extracellular microRNAs with new-onset breast cancer in the Framingham heart study.

Karlin H, Larson M, Rong J, Huan T, Courchesne P, Freedman J Am J Cancer Res. 2024; 14(11):5568-5572.

PMID: 39659926 PMC: 11626277. DOI: 10.62347/KMFI7371.

Dual Roles of microRNA-122 in Hepatocellular Carcinoma and Breast Cancer Progression and Metastasis: A Comprehensive Review.

Al Ageeli E Curr Issues Mol Biol. 2024; 46(11):11975-11992.

PMID: 39590305 PMC: 11592835. DOI: 10.3390/cimb46110711.

Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

Xu C, Jiang C, Li Z, Gao H, Xian J, Guo W MedComm (2020). 2024; 5(8):e660.

PMID: 39015555 PMC: 11247338. DOI: 10.1002/mco2.660.

Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement.

Zendjabil M Biochem Med (Zagreb). 2024; 34(2):020501.

PMID: 38882585 PMC: 11177657. DOI: 10.11613/BM.2024.020501.

The Impact of miR-122 on Cancer.

Wu S, Wu Y, Deng S, Lei X, Yang X Curr Pharm Biotechnol. 2024; 25(12):1489-1499.

PMID: 38258767 DOI: 10.2174/0113892010272106231109065912.

References

Thakral S, Ghoshal K . miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 2014; 15(2):142-50. PMC: 4439190. DOI: 10.2174/1566523214666141224095610. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Inns J, James V . Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease. Breast. 2015; 24(4):364-9. DOI: 10.1016/j.breast.2015.04.001. View

Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K . Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013; 424:99-103. DOI: 10.1016/j.cca.2013.05.021. View

Yang J, Yuan Y, Yang X, Hong Z, Yang L . Decreased expression of microRNA-122 is associated with an unfavorable prognosis in childhood acute myeloid leukemia and function analysis indicates a therapeutic potential. Pathol Res Pract. 2017; 213(9):1166-1172. DOI: 10.1016/j.prp.2017.06.017. View

Serpico D, Molino L, Di Cosimo S . microRNAs in breast cancer development and treatment. Cancer Treat Rev. 2013; 40(5):595-604. DOI: 10.1016/j.ctrv.2013.11.002. View

Zhou W, Fong M, Min Y, Somlo G, Liu L, Palomares M . Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4):501-15. PMC: 4016197. DOI: 10.1016/j.ccr.2014.03.007. View

El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W . Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol. 2014; 6(11):818-24. PMC: 4243156. DOI: 10.4254/wjh.v6.i11.818. View

Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I . Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015; 448:228-31. DOI: 10.1016/j.cca.2015.06.022. View

10.

Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes H . MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008; 47(4):1223-32. DOI: 10.1002/hep.22158. View

11.

Xu M, Ren Z, Wang X, Comer A, Frank J, Ke Z . ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis. Mol Cancer. 2016; 15(1):52. PMC: 4944437. DOI: 10.1186/s12943-016-0532-4. View

12.

Cho H, Kim J, Nam J, Wang H, Lee J, Kim B . High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clin Biochem. 2015; 48(16-17):1073-8. DOI: 10.1016/j.clinbiochem.2015.06.019. View

13.

Fong M, Zhou W, Liu L, Alontaga A, Chandra M, Ashby J . Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015; 17(2):183-94. PMC: 4380143. DOI: 10.1038/ncb3094. View

14.

Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M . Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 2012; 18(21):5972-82. DOI: 10.1158/1078-0432.CCR-12-1407. View

15.

Friese C, Harrison J, Janz N, Jagsi R, Morrow M, Li Y . Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017; 123(11):1925-1934. PMC: 5444953. DOI: 10.1002/cncr.30547. View

16.

Shayestehpour M, Moghim S, Salimi V, Jalilvand S, Yavarian J, Romani B . Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy. Virus Res. 2017; 240:207-214. DOI: 10.1016/j.virusres.2017.08.016. View

17.

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

18.

Cheung K, Graves C, Robertson J . Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000; 26(2):91-102. DOI: 10.1053/ctrv.1999.0151. View

19.

Luo Y, Wang X, Niu W, Wang H, Wen Q, Fan S . Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients. Oncol Lett. 2017; 13(2):867-874. PMC: 5351301. DOI: 10.3892/ol.2016.5482. View

20.

Wang B, Wang H, Yang Z . MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS One. 2012; 7(10):e47053. PMC: 3466252. DOI: 10.1371/journal.pone.0047053. View